Reset Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Reset Pharmaceuticals is a private, pre-clinical stage biotech targeting the urgent and underserved mental health condition of demoralization syndrome in oncology patients. Its lead asset, RSTP-1000, is a proprietary psilocybin-inspired therapy in development, leveraging a worldwide license from NYU based on the seminal work of Dr. Stephen Ross. The company is positioning itself in a high-value oncology supportive care market with no approved treatments, aiming to offer a rapid and durable therapeutic alternative to ineffective antidepressants.

PsychiatryOncology Supportive Care

Technology Platform

Development of proprietary, psilocybin-inspired small molecule therapies designed to reset neural networks by modulating dopamine pathways, specifically targeting the nucleus accumbens to address morale-based disorders.

Opportunities

Targets a large, completely underserved patient population (250k+ annual cases in US) with zero approved therapies, creating a potential first-mover advantage.

The high-cost oncology market may support premium pricing for a drug that improves patient quality of life and outcomes.

A successful treatment could expand into other conditions involving demoralization, such as other progressive life-altering diseases.

Risk Factors

High clinical risk associated with developing a Schedule I psychedelic compound for a psychiatric endpoint that may require regulatory validation.

Significant commercialization risk due to the need for specialized administration settings and challenging payer reimbursement negotiations.

Intense competition in the broader psychedelic therapeutics space from better-funded entities.

Competitive Landscape

Direct competition for demoralization syndrome is currently non-existent. However, Reset operates in the broader competitive field of companies developing psilocybin-based therapies (e.g., Compass Pathways, Usona Institute, Cybin) for major depressive disorder (MDD) and treatment-resistant depression (TRD). These companies have more advanced clinical programs and greater resources. Reset's niche focus is its primary defense, but if its approach proves successful, it could attract competition from these larger players or oncology-focused biopharma companies.

More companies in Neuroscience & CNS →More companies in United States →